SENSEI BIOTHERAPEUTICS INC (SNSE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.85+6.54%
Close 2026-06-15 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Negative cash from operations near or below $10.7M in 2026-Q1: metric not reported.
Sensei Biotherapeutics is advancing clinical programs despite operating losses near $171M in 2026-Q1. The company manages cash burn with negative cash flow of $10.7M in 2026-Q1. Recent CEO promotion and M&A activity show positive management moves.
The company is loss-making with EPS estimates worsening to -$104.31 for 2026. Operating losses have increased sharply from about -$8M in 2024 to -$171M in 2026-Q1. The stock has fallen over 60% from its high, reflecting weak fundamentals.
The market is selling off sharply with a 60% drawdown, reflecting skepticism about the turnaround. No clear consensus revenue or EPS growth is priced in, and recent EPS estimates show deep losses.
Breaks if: cash burn worsens beyond negative $10.7M in 2026-Q1
Continue to manage significant operating losses and negative cash flow from operations while advancing clinical programs.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious due to ongoing losses and management's struggle to reduce cash burn.
The market seems to have priced in significant uncertainty, reflected in the low confidence and elevated risk levels. Expectations are low, particularly given the company's recent financial struggles compared to its peers.
Fundamentals are likely to remain weak in the near term, as the company continues to report significant operating losses. Management's focus on advancing clinical data is positive, but cash burn remains a concern.
The long-term thesis hinges on the outcomes of upcoming clinical trials and the overall performance of the healthcare sector. Key factors include the potential for guidance cuts and the impact of broader economic conditions on the company's performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 6 of last 6 quarters. Operating losses remain significant with operating income of -$18.4M in 2026-Q2 and -$170.6M in 2026-Q1; cash from operations was negative $15.7M in 2026-Q2 and $10.7M in 2026-Q1. Management continues to manage high cash burn consistent with advancing clinical-stage programs, indicating limited progress in reducing losses so far.
“Operating income was -$18.4M and cash from operations was -$15.7M.”
“Operating income was -$170.6M and cash from operations was -$10.7M.”
“Operating income was -$4.96M and cash from operations was -$3.86M.”
“Operating income was -$4.85M and cash from operations was -$3.59M.”
“Operating income was -$5.21M and cash from operations was -$5.91M.”
“Operating income was -$7.27M and cash from operations was -$7.09M.”
Breaks if: EPS loss worsens beyond -104.31 USD in 2026
Breaks if: operating losses worsen beyond negative $170M in 2026-Q1
Continue to manage significant operating losses and negative cash flow from operations while advancing clinical programs.
Stated as a priority in 6 of last 6 quarters. Operating losses remain significant with operating income of -$18.4M in 2026-Q2 and -$170.6M in 2026-Q1; cash from operations was negative $15.7M in 2026-Q2 and $10.7M in 2026-Q1. Management continues to manage high cash burn consistent with advancing clinical-stage programs, indicating limited progress in reducing losses so far.
“Operating income was -$18.4M and cash from operations was -$15.7M.”
“Operating income was -$170.6M and cash from operations was -$10.7M.”
“Operating income was -$4.96M and cash from operations was -$3.86M.”
“Operating income was -$4.85M and cash from operations was -$3.59M.”
“Operating income was -$5.21M and cash from operations was -$5.91M.”
“Operating income was -$7.27M and cash from operations was -$7.09M.”
In the next 1 to 3 years, SNSE's path will depend heavily on clinical progress and sector trends. Not investment advice.